Paper Details

  1. Home
  2. Paper Details

BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition.

Author: ArganiPedram, DomeJeffrey S, DunnEmily, FriedmanAlan D, JiangLiQun, ObasajuPatience, PratilasChristine A, RheeDaniel S, ShahabShubin

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Wilms tumor (WT) is the most common renal malignancy in childhood. This case report describes a child with recurrent, pulmonary metastatic, favorable histology WT harboring a BRAF V600E mutation. The patient initially responded to standard chemotherapy but relapsed. Following confirmation of the BRAF V600E mutation, the patient received combination therapy with dabrafenib and trametinib, leading to a complete radiographic response. This is the first reported case of effective BRAF/MEK targeted therapy in a pediatric Wilms tumor patient.
Paper Details　
Original Abstract of the Article :
Wilms tumor (WT) is the most common renal malignancy of childhood and accounts for 6% of all childhood malignancies. With current therapies, the 5-yr overall survival (OS) for children with unilateral favorable histology WT is greater than 85%. The prognosis is worse, however, for the roughly 15% of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133746/

データ提供：米国国立医学図書館（NLM）

A Rare Oasis in the Desert of Childhood Cancer: Targeted Therapy for Wilms Tumor

Wilms tumor, a type of kidney cancer that primarily affects children, is like a harsh desert environment that can be difficult to navigate. This research explores the potential of targeted therapy, using BRAF/MEK inhibitors, for treating a rare and aggressive form of this cancer. It's like discovering a hidden spring of hope within the arid landscape, offering a new path for treating this challenging disease.

A Beacon of Hope: Targeted Therapy Shows Promise

The case study presented in this research highlights the effectiveness of a BRAF/MEK inhibitor combination therapy in treating a child with recurrent and metastatic Wilms tumor. This is like finding a rare oasis in the desert, offering respite and a chance for survival. The patient experienced a complete radiographic response to treatment, showcasing the potential of this targeted approach for treating this aggressive form of cancer.

Navigating the Desert of Childhood Cancer: A New Path Forward

This research provides a glimmer of hope for children battling this challenging disease. It demonstrates the potential of targeted therapies to effectively treat rare and aggressive forms of Wilms tumor. Just as a camel caravan uses a compass to navigate the desert, researchers are continually searching for new and innovative ways to treat childhood cancers, offering hope for a brighter future for children facing these challenges.

Dr. Camel's Conclusion

This research offers a compelling case study highlighting the potential of BRAF/MEK inhibitor combination therapy for treating a rare and aggressive form of Wilms tumor. It provides a beacon of hope for children battling this challenging disease, reminding us that even in the vast and unforgiving desert of cancer, new pathways for treatment can be discovered. As researchers, we must continue to explore and develop innovative approaches to fight childhood cancers, offering a brighter future for these young warriors.

Date :
  1. Date Completed 2021-05-27
  2. Date Revised 2021-05-27
Further Info :

Pubmed ID

32238401

DOI: Digital Object Identifier

PMC7133746

Related Literature

Article Analysis
・Side Effects of trametinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.